Author:
Cannata-Andía Jorge B.,Carrillo-López Natalia,Rodriguez-García Minerva,Torregrosa José-Vicente
Publisher
Springer International Publishing
Reference60 articles.
1. KDIGO clinical practice guideline for the diagnosis. Evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2009;113:S1–130.
2. Cannata-Andía JB, Martín-Carro B, Martín-Vírgala J, Rodríguez-Carrio J, Bande-Fernández JJ, Alonso-Montes C, et al. Chronic kidney disease-mineral and bone disorders: pathogenesis and management. Calcif Tissue Int. 2020;108:410.
3. Olgaard K, Salusky I, Silver J, editors. The spectrum of mineral and bone disorders in chronic kidney disease. Oxford: Oxford University Press; 2010.
4. Centeno PP, Herberger A, Mun HC, Tu C, Nemeth EF, Chang W, et al. Phosphate acts directly on the calcium-sensing receptor to stimulate parathyroid hormone secretion. Nat Commun. 2019;10(1):4693.
5. Gattineni J, Bates C, Twombley K, Dwarakanath V, Robinson ML, Goetz R, et al. FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. Am J Physiol Renal Physiol. 2009;297(2):F282–91.